Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/52830
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Java A. | - |
dc.contributor.author | Bomback A.S. | - |
dc.contributor.author | Kavanagh D. | - |
dc.contributor.author | Remuzzi G. | - |
dc.contributor.author | Sunder-Plassmann G. | - |
dc.contributor.author | Kanellis J. | - |
dc.contributor.author | Daina E. | - |
dc.contributor.author | Walker P.D. | - |
dc.contributor.author | Wang Z. | - |
dc.contributor.author | Ahmad Z. | - |
dc.contributor.author | Fakhouri F. | - |
dc.date.accessioned | 2025-01-06T02:50:45Z | - |
dc.date.available | 2025-01-06T02:50:45Z | - |
dc.date.copyright | 2024 | - |
dc.date.issued | 2024-11-13 | en |
dc.identifier.citation | Journal of the American Society of Nephrology. Conference: Kidney Week 2024. San Diego, CA United States. 35(pp 1080), 2024. Date of Publication: 2024. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/52830 | - |
dc.description.abstract | Background: Pegcetacoplan (Peg; targeted C3/C3b inhibitor) may prevent kidney damage in C3G and primary IC-MPGN. NOBLE (NCT04572854) randomized 13 patients with post-transplant recurrent C3G or primary IC-MPGN. At week 12, Peg was well tolerated and showed improvements in histologic, clinical, and biomarker parameters of disease. Method(s): We conducted a post-hoc analysis of 9 NOBLE patients treated with subcutaneous Peg 1080 mg twice weekly plus standard of care for 52 weeks; of these, treatment completers had >80% compliance (n=7). Result(s): At week 52, 5/9 (55.6%) patients had reduced C3c staining (p=0.0423 vs baseline). 7/9 (77.8%) had decreased activity score compared to baseline and 2/8 (25%) had absent electron microscopy deposits at week-52 biopsy. Patients with >1 g/g proteinuria at baseline had a median 56.4% decrease in proteinuria (Table). 7/9 (77.8%) patients had stable/improved estimated glomerular filtration rate, and 8/9 (88.9%) had both increased serum C3 and decreased sC5b-9. No meningitis cases, graft losses, or deaths were reported. Non-serious rejection episodes were reported for 2/9 (22.2%) patients. 1 patient (11.1%) discontinued for serious adverse event of weight loss. Conclusion(s): By inhibiting the breakdown of C3, Peg achieved meaningful histology improvements for 8/9 (88.9%) patients while also improving disease parameters, increasing serum C3, and decreasing plasma sC5b-9. The Phase 3 VALIANT (NCT05067127) trial will further evaluate the safety and efficacy of Peg in patients with native kidney or post-transplant C3G or primary IC-MPGN. | - |
dc.relation.ispartof | Journal of the American Society of Nephrology | - |
dc.subject.mesh | electron microscopy | - |
dc.subject.mesh | glomerulopathy | - |
dc.subject.mesh | graft failure | - |
dc.subject.mesh | histology | - |
dc.subject.mesh | membranoproliferative glomerulonephritis | - |
dc.subject.mesh | meningitis | - |
dc.subject.mesh | proteinuria | - |
dc.title | Pegcetacoplan for post-transplant recurrent c3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN) in noble: 52-week patient evolution. | - |
dc.type | Conference Abstract | - |
dc.identifier.affiliation | Nephrology | - |
dc.description.conferencename | Kidney Week 2024 | - |
dc.description.conferencelocation | San Diego, CA, United States | - |
dc.type.studyortrial | Clinical trial | - |
local.date.conferencestart | 2024-10-23 | - |
dc.identifier.institution | (Java) Washington University in St Louis School of Medicine, St Louis, MO, United States | - |
dc.identifier.institution | (Bomback) Columbia University, Irving Medical Center, New York, NY, United States | - |
dc.identifier.institution | (Kavanagh) Newcastle University, Newcastle upon Tyne, United Kingdom | - |
dc.identifier.institution | (Remuzzi, Daina) Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy | - |
dc.identifier.institution | (Sunder-Plassmann) Medizinische Universitat Wien, Vienna, Austria | - |
dc.identifier.institution | (Kanellis) Monash Medical Centre, Clayton, VIC, Australia | - |
dc.identifier.institution | (Walker) Arkana Laboratories, Little Rock, AR, United States | - |
dc.identifier.institution | (Wang, Ahmad) Apellis Pharmaceuticals Inc, Waltham, MA, United States | - |
dc.identifier.institution | (Fakhouri) Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland | - |
local.date.conferenceend | 2023-06-06 | - |
dc.identifier.affiliationmh | (Kanellis) Monash Medical Centre, Clayton, VIC, Australia | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairetype | Conference Abstract | - |
Appears in Collections: | Conferences |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.